Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

27. April 2020 06:00 ET | Quelle: Pluristem Therapeutics, Inc.

The European Investment Bank (EIB), EU Delegation to Israel, the Israel Innovation Authority, and Pluristem Cordially Invite the Public to an Online Signing Ceremony on April 30, 2020

HAIFA, Israel, April 27, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
24. April 2020 06:00 ET | Quelle: Pluristem Therapeutics, Inc.

Pluristem Secures €50 Million Non-Dilutive Financing from the European Investment Bank to Support its COVID-19 Project and Phase III Studies

HAIFA, Israel, April 24, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
13. April 2020 06:00 ET | Quelle: Pluristem Therapeutics, Inc.

Pluristem Expands its Compassionate Use Program: Treated First COVID-19 Patient in U.S. Under FDA Single Patient Expanded Access Program

Cleared by FDA to proceed with the treatment in U.S. under Coronavirus Treatment Acceleration Program (CTAP)Pluristem’s main focus: multinational clinical trial of PLX cells for treatment of...
07. April 2020 07:50 ET | Quelle: Pluristem Therapeutics, Inc.

Pluristem Reports Preliminary Data from its COVID-19 Compassionate Use Program, Treating Seven Patients with Acute Respiratory Failure

All treated patients were in Intensive Care Units (ICU) on ventilators and suffered from Acute Respiratory Distress Syndrome (ARDS)100% survival rate for all seven patients6 patients completed 1 week...
30. März 2020 07:30 ET | Quelle: Pluristem Therapeutics, Inc.

Pluristem Treated First Three COVID-19 Patients in Israel under Compassionate Use

Expects to treat more patients in Israel in the coming daysCompany is in discussions with regulators in the U.S. and Europe to define its clinical strategy for COVID-19 HAIFA, Israel, March 30, 2020...
26. März 2020 08:00 ET | Quelle: Pluristem Therapeutics, Inc.

Pluristem Provides Update on COVID-19: Preparedness, Current Phase III Clinical Trials Status and Treatment Development Activity

HAIFA, Israel, March 26, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
17. März 2020 08:30 ET | Quelle: Pluristem Therapeutics, Inc.

Israeli Ministry of Health Clears a Path to Allow Per Patient Compassionate Use Treatment of Covid-19 Patients with Pluristem’s PLX Cells

HAIFA, Israel, March 17, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
12. März 2020 09:00 ET | Quelle: Pluristem Therapeutics, Inc.

Pluristem and Charité University of Medicine Berlin Join Forces Targeting Potential Treatment for Respiratory and Inflammatory Intratissue Complications Caused by COVID-19

HAIFA, Israel, March 12, 2020 (GLOBE NEWSWIRE) -- HAIFA, Israel, March 12, 2020 - Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform...
03. März 2020 07:00 ET | Quelle: Pluristem Therapeutics, Inc.

Pluristem Receives Response from U.S. BARDA for Acute Radiation Syndrome Research Proposal

HAIFA, Israel, March 03, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
10. Februar 2020 07:00 ET | Quelle: Pluristem Therapeutics, Inc.

Pluristem Therapeutics CEO Issues Shareholder Update

HAIFA, Israel, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel cell therapy products,...

Vorherige Seite

Nächste Seite